Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) faced a turbulent week as its shares plunged 17%, desp...
Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab a...
Telesis Bio has announced a licensing agreement with Regeneron, enabling the latter to deploy the Gi...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has entered a key licensing agreement with Telesis Bio...
SAN DIEGO--(BUSINESS WIRE)--Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA syn...